In 2019, Professor Lynne Emmerton led the review of name similarity for:
- Monoclonal antibodies (MABs) (commonly ending in the suffix ‘mab’)
- Tyrosine kinase (factor) inhibitors (TKIs) (commonly ending in the suffix ‘nib’).
This included the theoretical risk of confusion within these classes of medicines in clinical practice, including the similarity in clinical indication, with a view to producing a specialised list of medicines. The results of this review can be found in this publication.